TARS insider ownership: who sold, why, and what they still hold

What stands out

Routine activity: 64% of sales were under disclosed plans, and no insider sold more than 1% of vested holdings.

A share of stake is shown for 0 of the 9 officers and directors who sold. 14 are left out

Left out: Bobak Azamian, William Link, Seshadri Neervannan, Bryan Wahl, Aziz Mottiwala, Dianne Whitfield, Jeffrey Farrow, Elizabeth Lin, Andrew Goldberg, Wendy Yarno, Scott Morrison, Bhaskar Chaudhuri, David Pyott and Katherine Goodrich (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Bobak Azamian

President/CEO and Board Chair, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$5.2M54% planned, 46% to cover taxes

William Link

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$4.5MDisclosed plan

Dianne Whitfield

Chief Human Resources Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.7M69% planned, 31% to cover taxes

Elizabeth Lin

Chief Medical Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.4M90% planned, 10% to cover taxes

Seshadri Neervannan

Chief Operating Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.0M61% planned, 39% to cover taxes

All 9 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 17, 2026 to Oct 16, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Sep 15, 2026William Link sold 13K shares ($980K) under a disclosed trading plan. 201 shares came in from vesting or option exercises the same day, so the holding fell by 12K net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
William Link Director	12,500	$78.38	n/a	n/a	Sep 15, 2026	Sep 17, 2026

Outside holders, reported separately

William Link reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Tarsus Pharmaceuticals, Inc. CEO selling stock?

Yes. Bobak Azamian sold 71K shares ($5.2M) in the past 12 months, 54% of it under a trading plan disclosed in the filings.

Why are Tarsus Pharmaceuticals, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 64% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 36% were to cover taxes. A trading plan schedules sales in advance.

Are any Tarsus Pharmaceuticals, Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold9 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Bobak Azamian President/CEO and Board Chair, Director	$5.2M 71K shares	Not confirmed share of stake is being verified. Why	54% under a disclosed plan, 46% to cover taxes
William Link Director	$4.5M 60K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Dianne Whitfield Chief Human Resources Officer	$2.7M 35K shares	Not confirmed share of stake is being verified. Why	69% under a disclosed plan, 31% to cover taxes
Elizabeth Lin Chief Medical Officer	$2.4M 29K shares	Not confirmed share of stake is being verified. Why	90% under a disclosed plan, 10% to cover taxes
Seshadri Neervannan Chief Operating Officer	$2.0M 27K shares	Not confirmed share of stake is being verified. Why	61% under a disclosed plan, 39% to cover taxes
Jeffrey Farrow Chief Financial Officer and Chief Strategy Officer	$1.3M 21K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Aziz Mottiwala Chief Commercial Officer	$893K 13K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Bryan Wahl General Counsel	$850K 12K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Katherine Goodrich Director	$183K 3K shares	Not confirmed share of stake is being verified. Why	Disclosed plan

Board members representing outside shareholders, reported separately: William Link. Details

The full ownership picture0 of 14 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 16, 2025

Sold

Held Oct 16, 2026

Still held

Bobak Azamian

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Bobak Azamian are complete.

President/CEO and Board Chair, Director

n/a

−71K

n/a

Vesting, gifts, unvested awards and holding lines for Bobak Azamian

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Bobak Azamian are complete; balances and unit counts will be added when the check is finished.

−52Kgifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
136,947	$35.50	Mar 6, 2034	$6.1M
90,736	$44.54	Mar 4, 2035	$3.2M
96,723	$74.90	Mar 4, 2036	$494K

Estimate: options held × ($80.01 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

William Link

Director

n/a

−60K

n/a

Vesting, gifts, unvested awards and holding lines for William Link

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for William Link are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,000	$33.14	Jun 12, 2034	$234K
4,540	$40.95	Jun 11, 2035	$177K
3,837	$64.34	Jun 24, 2036	$60K

Estimate: options held × ($80.01 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Seshadri Neervannan

Chief Operating Officer

n/a

−27K

n/a

Vesting, gifts, unvested awards and holding lines for Seshadri Neervannan

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Seshadri Neervannan are complete; balances and unit counts will be added when the check is finished.

−475gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
47,500	$35.50	Mar 6, 2034	$2.1M
30,628	$44.54	Mar 4, 2035	$1.1M
27,310	$74.90	Mar 4, 2036	$140K

Estimate: options held × ($80.01 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Bryan Wahl

General Counsel

n/a

−12K

n/a

Vesting, gifts, unvested awards and holding lines for Bryan Wahl

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Bryan Wahl are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
42,500	$35.50	Mar 6, 2034	$1.9M
30,628	$44.54	Mar 4, 2035	$1.1M
27,310	$74.90	Mar 4, 2026	$140K

Estimate: options held × ($80.01 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Aziz Mottiwala

Chief Commercial Officer

n/a

−13K

n/a

Vesting, gifts, unvested awards and holding lines for Aziz Mottiwala

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Aziz Mottiwala are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
47,500	$35.50	Mar 6, 2034	$2.1M
33,691	$44.54	Mar 4, 2035	$1.2M
30,724	$74.90	Mar 4, 2036	$157K

Estimate: options held × ($80.01 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Dianne Whitfield

Chief Human Resources Officer

n/a

−35K

n/a

Vesting, gifts, unvested awards and holding lines for Dianne Whitfield

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Dianne Whitfield are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
42,500	$35.50	Mar 6, 2034	$1.9M
30,628	$44.54	Mar 4, 2035	$1.1M
27,310	$74.90	Mar 4, 2036	$140K

Estimate: options held × ($80.01 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Jeffrey Farrow

Chief Financial Officer and Chief Strategy Officer

n/a

−21K

n/a

Vesting, gifts, unvested awards and holding lines for Jeffrey Farrow

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jeffrey Farrow are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
47,500	$35.50	Mar 6, 2034	$2.1M
30,628	$44.54	Mar 4, 2035	$1.1M
30,724	$74.90	Mar 4, 2036	$157K

Estimate: options held × ($80.01 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Elizabeth Lin

Chief Medical Officer

n/a

−29K

n/a

Vesting, gifts, unvested awards and holding lines for Elizabeth Lin

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Elizabeth Lin are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,000	$26.25	Jan 24, 2034	$538K
5,000	$33.14	Jun 12, 2034	$234K
41,074	$46.21	Nov 3, 2034	$1.4M
15,314	$44.54	Mar 4, 2035	$543K
27,310	$74.90	Mar 4, 2036	$140K

Estimate: options held × ($80.01 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Andrew Goldberg

Director

n/a

Vesting, gifts, unvested awards and holding lines for Andrew Goldberg

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Andrew Goldberg are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,000	$33.14	Jun 12, 2034	$234K
4,540	$40.95	Jun 11, 2035	$177K
3,837	$64.34	Jun 24, 2036	$60K

Estimate: options held × ($80.01 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Wendy Yarno

Director

n/a

Vesting, gifts, unvested awards and holding lines for Wendy Yarno

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Wendy Yarno are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,000	$33.14	Jun 12, 2034	$234K
4,540	$40.95	Jun 11, 2035	$177K
3,837	$64.34	Jun 24, 2036	$60K

Estimate: options held × ($80.01 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Scott Morrison

Director

n/a

Vesting, gifts, unvested awards and holding lines for Scott Morrison

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Scott Morrison are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,000	$33.14	Jun 12, 2034	$234K
4,540	$40.95	Jun 11, 2035	$177K
3,837	$64.34	Jun 24, 2036	$60K

Estimate: options held × ($80.01 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Bhaskar Chaudhuri

Director

n/a

Vesting, gifts, unvested awards and holding lines for Bhaskar Chaudhuri

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Bhaskar Chaudhuri are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,000	$33.14	Jun 12, 2034	$234K
4,540	$40.95	Jun 11, 2035	$177K
3,837	$64.34	Jun 24, 2036	$60K

Estimate: options held × ($80.01 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

David Pyott

Director

n/a

Vesting, gifts, unvested awards and holding lines for David Pyott

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Pyott are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
7,000	$12.97	Jun 19, 2032	$469K
2,500	$18.27	Jul 31, 2033	$154K
2,500	$32.76	Apr 23, 2034	$118K
2,128	$49.97	Apr 23, 2035	$64K
5,893	$63.27	Feb 17, 2036	$99K
3,837	$64.34	Jun 24, 2036	$60K

Estimate: options held × ($80.01 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Katherine Goodrich

Director

n/a

−3K

n/a

Vesting, gifts, unvested awards and holding lines for Katherine Goodrich

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Katherine Goodrich are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,000	$46.51	Nov 12, 2034	$335K
4,540	$40.95	Jun 11, 2035	$177K
3,837	$64.34	Jun 24, 2036	$60K

Estimate: options held × ($80.01 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Holdings and share of stake for Tarsus Pharmaceuticals, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$20.0M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $20.0M across 271,557 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $12.7M · 64%

36%

The lighter segment is sales with no plan disclosed in the filing ($7.3M), including tax-related sales outside a plan.

Taxes

$7.3M of sales (36.5%) cite tax obligations in their footnotes. Example: Jeffrey Farrow, Jun 16, 2026

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Bobak Azamian President/CEO and Board Chair, Director	71K	$5.2M	54%	26%	Dec 24, 2025 to Sep 4, 2026
William Link Director	60K	$4.5M	100%	22%	Dec 15, 2025 to Sep 15, 2026
Dianne Whitfield Chief Human Resources Officer	35K	$2.7M	69%	13%	Dec 16, 2025 to Mar 19, 2026
Elizabeth Lin Chief Medical Officer	29K	$2.4M	90%	12%	Dec 16, 2025 to Sep 4, 2026
Seshadri Neervannan Chief Operating Officer	27K	$2.0M	61%	10%	Mar 4, 2026 to Sep 4, 2026
Jeffrey Farrow Chief Financial Officer and Chief Strategy Officer	21K	$1.3M	0%	7%	Mar 17, 2026 to Jun 16, 2026
Aziz Mottiwala Chief Commercial Officer	13K	$893K	0%	4%	Mar 17, 2026 to Mar 19, 2026
Bryan Wahl General Counsel	12K	$850K	0%	4%	Mar 17, 2026 to Mar 19, 2026
Katherine Goodrich Director	3K	$183K	100%	0.9%	Jun 15, 2026 to Jun 15, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$0	$0	$0	$0
Dec 2025	$3.1M	$3.0M	$165K	$0
Jan 2026	$1.3M	$1.3M	$0	$0
Feb 2026	$0	$0	$0	$0
Mar 2026	$7.9M	$1.7M	$6.2M	$0
Apr 2026	$0	$0	$0	$0
May 2026	$0	$0	$0	$0
Jun 2026	$2.5M	$1.6M	$877K	$0
Jul 2026	$0	$0	$0	$0
Aug 2026	$0	$0	$0	$0
Sep 2026	$5.2M	$5.2M	$0	$0
Oct 2026	$0	$0	$0	$0

Board members representing outside shareholders (1)Listed and sourced; not part of the management totals or the answer line

Directors whose reported holdings sit mostly in an investment fund or a corporate shareholder they represent, not in their own name, with beneficial ownership disclaimed except for their own financial interest. Listed and sourced here; not part of the management totals or the answer line. Shares a fund hands to its own investors are distributions, not sales.

Board member	Held Oct 16, 2025	Sold	Held Oct 16, 2026	Still held
William Link ! Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for William Link are complete. Director	n/a	0	n/a	n/a
Vesting, gifts, unvested awards and holding lines for William Link Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for William Link are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts)

Is this normal? Selling year by year5 earlier years to compare with

More than usual: $20.0M sold, after almost none in the past 5 years. 9 insiders sold; the average is 6 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 16, 2026 Latest 12 months	272K	9	$20.0M
Oct 16, 2025 1 year earlier	140K	8	$6.8M
Oct 16, 2024 2 years earlier	122K	7	$2.7M
Oct 17, 2023 3 years earlier	352K	8	$6.0M
Oct 17, 2022 4 years earlier	75K	4	$1.5M
Oct 17, 2021 5 years earlier	38K	3	$950K

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty14 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Tarsus Pharmaceuticals, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology328 filings on record, 60 filed in the 12-month period, and how we read them

All 328 Forms 3, 4 and 5 on record for Tarsus Pharmaceuticals, Inc. (SEC CIK 1819790), filed from Oct 15, 2020 to Sep 17, 2026; 60 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 16, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (10)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Rosemary Crane	Jun 25, 2024	5,350 shares, last reported balance as of Jun 24, 2024
Jose Trevejo	Dec 22, 2023	2,251 shares, last reported balance as of Dec 20, 2023
Leonard Greenstein	Apr 21, 2023	26,785 shares, last reported balance as of Apr 20, 2023
Mark Holdbrook	Mar 21, 2023	3,191 shares, last reported balance as of Mar 20, 2023
Michael Ackermann	Jul 1, 2022	1,308,273 shares, last reported balance as of Jun 15, 2022
Vivo Capital IX, LLC	May 5, 2022	5,714,036 shares, last reported balance as of May 5, 2022
Jason Tester	Jun 17, 2021	66,172 shares, last reported balance as of Oct 20, 2020
Jason Tester	Jun 17, 2021	1,920,933 shares, last reported balance as of Oct 20, 2020
RTW INVESTMENTS, LP	May 7, 2021	2,013,601 shares, last reported balance as of May 7, 2021
Frazier Life Sciences IX, L.P.	Oct 20, 2020	1,917,157 shares, last reported balance as of Oct 20, 2020

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Tarsus Pharmaceuticals, Inc. insiders sold $20.0M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the Tarsus Pharmaceuticals, Inc. CEO selling stock?

Why are Tarsus Pharmaceuticals, Inc. insiders selling?

Are any Tarsus Pharmaceuticals, Inc. insiders buying?

The evidence

Taxes

Sales by month